Loading clinical trials...
Loading clinical trials...
An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c \>10% \</=12% who are treated with ITCA 650 20 mcg/day for 13 weeks followed by ITCA 650 ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Intarcia Therapeutics
NCT07232537 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
NCT06815081 · Type 1 Diabetes (T1D), Type 2 Diabetes
NCT06003153 · Genetic Predisposition, Metabolic Diseases, and more
NCT06278207 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
NCT07051005 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM)
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama
Fundamental Research
Gulf Shores, Alabama
East Valley Family Physicians, PLC
Chandler, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions